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Tumor-associated macrophages (TAMs) play a central role in tumor progression, metas-
tasis, and recurrence after treatment. Macrophage plasticity and diversity allow their 
classification along a M1–M2 polarization axis. Tumor-associated macrophages usually 
display a M2-like phenotype, associated with pro-tumoral features whereas M1 macro-
phages exert antitumor functions. Targeting the reprogramming of TAMs toward M1-like 
macrophages would thus be an efficient way to promote tumor regression. This can be 
achieved through therapies including chemotherapy, immunotherapy, and radiotherapy 
(RT). In this review, we first describe how chemo- and immunotherapies can target 
TAMs and, second, we detail how RT modifies macrophage phenotype and present the 
molecular pathways that may be involved. The identification of irradiation dose inducing 
macrophage reprogramming and of the underlying mechanisms could lead to the design 
of novel therapeutic strategies and improve synergy in combined treatments.
Keywords: tumor-associated macrophages, reprogramming, polarization immunotherapy, chemotherapy, 
radiotherapy, nuclear factor kappa B, reactive oxygen species
Abbreviations: AMPK, AMP-activated protein kinase; AP-1, activator protein 1; Arg 1, arginase 1; ATM, ataxia telangiectasia 
mutated; C/EBPβ, CCAAT-enhancer-binding proteins; CCL, chemokine ligand; CCR2, C–C chemokine receptor type 2; CD206, 
cluster of differentiation 206 or mannose receptor; CL, clodrolip; COX, cyclooxygenase; CpG-ODN, unmethylated cytosine-
guanine (CpG) oligodeoxynucleotides; CSF-1, colony-stimulating factor 1; CSF-1R, colony-stimulating factor 1 receptor; CTLA4, 
cytotoxic T lymphocyte-associated protein 4; CXCL12, C–X–C motif chemokine 12; ECM, extracellular matrix; ERK, extracellular 
signal-regulated kinase, FDA, food and drug administration; FRβ, folate receptor β; HDI, high doses of irradiation; HIF, hypoxia-
inducible factor; HLA-DR, human leukocyte antigen-cell surface receptor; HO1, heme oxygenase 1; HRG, histidine-rich glyco-
protein; IFNγ, interferon γ; IL, interleukin; iNOS, inducible nitric oxide synthase; IR, ionizing radiation; IRF, interferon-regulatory 
factor; JNK, c-Jun N-terminal kinase; KLF4, Kruppel-like factor 4; LDI, low doses of irradiation; LET, linear energy transfer; LLC, 
Lewis lung cancer; LPS, lipopolysaccharide; mAb, monoclonal antibody; MAPK, mitogen-activated protein kinase; MARCO, 
pattern recognition scavenger receptor; MCP-1, monocyte chemoattractant protein 1; M-CSF, macrophage colony-stimulating 
factor; MDI, moderate doses of irradiation; MHC, major histocompatibility complex; MMP, matrix metalloproteinase; MnSOD, 
manganese superoxide dismutase; MPK1, MAPK phosphatase 1; MRC1, mannose receptor-C 1; NAC, N-acetyl cysteine; NADPH, 
nicotinamide adenine dinucleotide; NEMO, NFκB essential modulator; NFκB, nuclear factor kappa B; NK, natural killer; NO, 
nitric oxide; NOX, NADPH oxidase; Nrf2, nuclear erythroid derived 2-related factor; p38, MAPK; PAMPs, pathogen-associated 
molecular patterns; PD-1, programmed cell death 1; PD-L1, programmed death ligand 1; PDA, pancreatic ductal adenocarcinoma; 
PEC, peritoneal exudate cells; PI3Kγ, phosphoinositide 3-kinase gamma; PlGF, placental growth factor; PPARγ, peroxisome 
proliferator-activated receptor gamma; RANTES, regulated on activation, T cell expressed and secreted; RELMα, resistin-like 
molecule alpha; RNS, reactive nitrogen species; ROS, reactive oxygen species; RT, radiotherapy; STAT, signal transducer and 
activator of transcription; SUMO, small ubiquitin-like modifier; TAMs, tumor-associated macrophages; TGFβ, transforming 
growth factor β; TLR, toll-like receptor; TNFα, tumor necrosis factor α; TRAIL-R2, TNFα-related apoptosis-inducing ligand 
receptor; VCAN, versican, extracellular matrix proteoglycan; VEGF, vascular endothelial growth factor; ZA, zoledronic acid.
2Genard et al. Moderate X-ray Doses for TAM Reprogramming
Frontiers in Immunology | www.frontiersin.org July 2017 | Volume 8 | Article 828
iNTRODUCTiON
In 1863, Rudolf Virchow was the first to highlight the infiltration 
of leukocytes in tumor, thereby proposing a link between inflam-
mation and tumorigenesis. Two centuries later, an inflammatory 
microenvironment within the tumor is part of the hallmarks of 
cancer (1). In fact, in emerging cancer disease, inflammation is 
a two-edge sword. On the one hand, the immune system can 
recognize tumor cells and kill them. On the other hand, chronic 
inflammation promotes cancer invasion, angiogenesis, and 
immunosuppression (2, 3). In this context, the immune system 
was assigned tumor immunoediting functions. The emergence 
of neoplastic cells induces an inflammatory environment, con-
tributing to the rejection of the tumor (the elimination phase). 
However, the immune system establishes a selective pressure on 
cancer cells hence selecting resistant cells (the equilibrium phase). 
Finally, tumor evades from the immune system and moves into 
the escape phase (4). This last phase can occur through different 
mechanisms: reduced immune recognition, increased cancer cell 
resistance or survival, and immunosuppressive tumor microenvi-
ronment (5). In this process, macrophages act as an orchestrator 
of inflammation and are the main players of immunosurveillance. 
In the elimination phase, transformed cells are recognized and 
their antigens are presented to the effectors of the immune system 
by macrophages, promoting antitumor immunity (6). However, 
in the escape phase, macrophages play an important role in tumor 
progression by stimulating angiogenesis, metastasis, tumor 
growth, and immunosuppression notably through the secre-
tion of polyamines, M-CSF, vascular endothelial growth factor 
(VEGF), IL-10, and transforming growth factor β (TGFβ) (5).
COMPLiCiTY OF TUMOR-ASSOCiATeD 
MACROPHAGeS (TAMs) iN TUMOR 
PROGReSSiON
More than 50% of tumor-infiltrating cells are macrophages, 
named TAMs (7, 8). The recruitment and accumulation of TAMs 
into tumors are initiated by macrophage chemoattractants [e.g., 
CCL2/monocyte chemoattractant protein 1 (MCP-1), colony-
stimulating factor 1 (CSF-1)] and it is well established that TAMs 
drive tumor progression (9, 10). In fact, cancer prognosis is 
closely linked to the number of TAMs with an inverse correla-
tion: increased number of TAMs is associated with a reduced 
cancer patient survival (11). In healthy tissues, macrophages offer 
a remarkable plasticity to efficiently respond to environmental 
cues (12). In tumors, an identical plasticity is described: TAMs 
are educated by the tumor microenvironment, providing multiple 
phenotypes with a range of functions (13). TAM phenotypes 
can be featured as a linear scale where M1 and M2 phenotypes 
represent the two extremes, similarly to the TH1–TH2 classifica-
tion (Figure  1). M1 macrophages are recognized as classically 
activated macrophages and show enhanced ability to phagocyte 
pathogens. More importantly, these cells have antitumoral prop-
erties. Macrophages can also be polarized into the M2 phenotype, 
the alternative activated state of macrophages. M2 macrophages 
are requested in infection-free healing circumstances and have 
pro-tumoral functions. The polarization of macrophages can be 
driven by different microenvironmental molecules and leads to 
the production by the macrophages of different cytokines and 
chemokines. M1 macrophages are activated during acute inflam-
mation by toll-like receptor (TLR) ligands [lipopolysaccharide 
(LPS)] or TH1 cytokines [interferon γ (IFNγ)–tumor necrosis fac-
tor α (TNFα)]. M1 macrophages display an enhanced production 
of pro-inflammatory cytokines (TNFα and interleukins: IL-1β, 
IL-2, IL-6, IL-12, IL-23), reactive oxygen species (ROS), nitric 
oxide (NO) and present antigens via major histocompatibility 
complex class II molecules (14). Stimulation of macrophages 
with IL-4/IL-13, IL-10, TGFβ, or glucocorticoids leads to the M2 
phenotype and the subsequent production of anti-inflammatory 
cytokines (IL-10, TGFβ) that have an inhibitory effect on 
cytotoxic CD8+ T  cells. Macrophages with M2 phenotype also 
express cell surface scavenger receptor (CD206), hemoglobin 
receptor (CD163) and produce extracellular matrix (ECM) 
components (14–16). M2 macrophages facilitate the resolution 
of inflammation and promote tissue repair by TH2 response, tis-
sue remodeling, and immune tolerance. They also favor tumor 
growth (17, 18). This phenotype can be subclassified into M2a, 
M2b, or M2c according to the roles these macrophages exert (19). 
In cancer disease, TAMs usually exhibit a M2 phenotype and par-
ticipate to tumor angiogenesis, tumor invasion and metastasis, 
immunosuppression and cell activation. All these features led 
Qian and Pollard to classify TAMs in six functional subtypes: 
angiogenic, immunosuppressive, invasive, metastasis associated, 
perivascular, and activated macrophages (20).
MOLeCULAR PATHwAYS FOR M1–M2 
POLARiZATiON
The polarization of macrophages is influenced by several mecha-
nisms driven by transcription factors and miRNAs (Figure  1). 
The activation of macrophages into M1 or M2 phenotype is 
mainly induced by interferon-regulatory factor/signal transducer 
and activator of transcription (IRF/STAT) signaling pathways. 
IRF3, IRF5, STAT1, and STAT5 are responsible for driving M1 
polarization while IRF4, STAT3, and STAT6 provide M2 activation 
signals (14, 21). Besides IRF/STAT transcription factors, hypoxia 
also influences macrophage polarization. The lack of oxygen can 
activate hypoxia-inducible factors (HIF) differently in M1 versus 
M2 macrophages. Indeed, TH1 cytokines are able to induce HIF1α 
stabilization, triggering M1 response whereas HIF2α is activated 
by TH2 cytokines in M2 macrophages. These differences rely on 
the ability of HIF1 and HIF2 to, respectively, activate or suppress 
NO synthesis (22). Furthermore, nuclear factor kappa B (NFκB) 
fulfills a central role in the pro-inflammatory macrophages (M1). 
Indeed, the active heterodimer NFκB (p50–p65) promotes the 
transcription of inflammatory genes while the inhibitory het-
erodimer NFκB (p50–p50) prevents the transcription of these 
genes in anti-inflammatory macrophages (M2). Other transcrip-
tion factors including AP-1, Kruppel-like factor 4 and PPARγ can 
modulate the activated state of macrophages. Finally, miRNA also 
interfere with the polarization of macrophages. Among miRNAs 
of interest, miR127, miR155, and miR223 are key regulators of 
M1 polarization (23, 24). In contrast, miR146-a promotes M2 
polarization while decreasing the expression of M1 markers (25).
FiGURe 1 | Macrophage polarization. Through the binding to their respective receptors, M1 stimuli [lipopolysaccharide (LPS), tumor necrosis factor α (TNFα), and 
interferon γ (IFNγ)] trigger the activation of several transcription factors. These factors include interferon-regulatory factor/signal transducer and activator of 
transcription (IRF/STAT) family members (IRF3, IRF5, STAT1, and STAT5), the active nuclear factor kappa B (NFκB) heterodimer (p50–p65) and HIF1. miR127,  
miR 155, and miR223 also regulates M1 polarization. When polarized in M1-like phenotype, macrophages produce specific cytokines (TNFα, IL-1β, IL-2, IL-6, IL-12, 
IL-23, IFNγ), chemokines (CXCL10) and other molecules [reactive oxygen species (ROS), nitric oxide (NO), inducible nitric oxide synthase (iNOS), human leukocyte 
antigen-cell surface receptor (HLA-DR)]. M1 phenotype plays key roles in inflammation, immunostimulation and an antibacterial and antitumoral responses. M2 
stimuli [IL-4, IL-13, IL-10, and transforming growth factor β (TGFβ)] bind to ILR4α, ILR10, or TGFβR to induce M2-like phenotype in macrophages. These stimuli 
activate several transcription factors: IRF/STAT family members (IRF4, STAT 3, and STAT6), the inhibitory NFκB homodimer (p50–p50) and HIF2. miR14a also 
influences M2 polarization. When polarized in M2-like phenotype, macrophages produce specific cytokines (IL-10), chemokines (CCL5, CCL17, CCL18, CCL22), 
and other proteins (CD163, CD206, Arg1, MMP-9, Fizz-1, Ym-1, and PD-L1). M2 macrophages exert diverse functions, such as tissue repair, matrix remodeling, 
angiogenesis, immunosuppression, and favor tumor growth.
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TARGeTiNG TAMs wiTH 
CHeMOTHeRAPY OR iMMUNOTHeRAPY
In response to microbial signals, tissue damage, cytokines and 
metabolic products, monocytes, and macrophages from healthy 
tissues are able to undergo reprogramming (12, 21, 26, 27). The 
pro-tumoral functions of TAMs and their ability to be repro-
grammed, from M2-like macrophages toward M1 phenotype, 
make them an attractive target for anticancer therapies. Currently, 
different approaches have been proposed to modulate TAMs: 
(1) depletion of TAMs; (2) inhibition of circulating monocyte 
recruitment into the tumor; (3) blockade of M2 phenotype; and 
(4) enhanced activation of M1 macrophages or reprogramming 
of TAMs toward M1-like macrophages (27, 28). Each of these 
approaches will be detailed here under (Figure 2).
Depletion of TAMs
Three alternatives are available to destroy TAMs in tumor 
(Figure  2A). The first way is the use of chemical compounds, 
especially bisphosphonates, such as clodronate encapsulated 
in liposomes [clodrolip (CL)]. These liposomes containing 
clodronate are phagocyted by macrophages and are disrupted by 
lysosomal processes, leading to the release of clodronate in the 
cells. Clodronate is metabolized to an analog of ATP, cytotoxic 
for macrophages (29). CL is currently used in immune research 
and clinical trials to eliminate macrophages and phagocytes in 
multiple malignancies. For example, TAM depletion with CL 
impaired tumor engraftment, reduced tumor growth, and favored 
mouse survival in a chronic lymphocytic leukemia model (30). 
However, despite its effective tumor regression effects, it also 
induced severe side effects such as sensitivity toward infections 
and weight loss in mice and patients (31–34). A similar approach 
was developed using zoledronic acid (ZA), which inhibited 
tumor progression, angiogenesis, and metastasis in association 
with sorafenib in two human hepatocellular carcinoma mouse 
models (34). ZA depleted matrix metalloproteinase 9 (MMP-9) 
expressing TAMs (M2-like macrophages) but also impaired the 
differentiation of myeloid cells into TAMs (35). However, ZA, as 
ibandronate (another bisphosphonate), has generated conflicting 
results.
FiGURe 2 | Targeting tumor-associated macrophages (TAMs) with chemo- and immunotherapies. Different approaches have been proposed to modulate TAMs:  
(A) Depletion of TAMs: different kinds of treatments are available to destroy TAMs in tumor: toxins (Shigella flexneri attenuated strain or immunotoxin), liposome 
containing bisphosphonates [clodrolip, zoledronic acid (ZA) or ibandronate], and peptide modification to induce cytotoxic lymphocyte activation (e.g., legumain). 
Depletion of macrophages in tumor induced effective tumor regression in mouse and patients. (B) Inhibition of circulating monocyte recruitment into the tumor: two 
main recruitment effectors can be targeted to inhibit the recruitment of monocyte to the tumor site: CCL2/C–C chemokine receptor type 2 (CCR2) and colony-
stimulating factor 1 (CSF-1)/CSF1-R. The use of monoclonal antibody against CCL2 (e.g., Carlumab) or CSF-1 inhibits tumor growth in mouse models and humans. 
Another way to prevent monocyte recruitment to the tumor site is the use of molecule targeting CCL2/CCR2 (e.g., bindarit) or CSF1/CSF1-R (e.g., BLZ945, 
PLX3397) pathways. (C) Blockade of M2 phenotype: the blockade of M2 phenotype can be achieved by targeting two main transcription factors: STAT3 (sorafenib, 
sunitinib, WP1066, and resveratrol) and STAT6 (4-HPR, leflunomid, TMX264, and AS1217499). All these inhibitors provide tumor regression and inhibited 
angiogenesis. (D) Enhanced activation of M1 macrophages or reprogramming of TAMs toward M1-like macrophages: TAM reprogramming into M1 macrophages 
can be achieved through the stimulation of STAT1 (IFNγ, vadimezan), AMPKα1 (metformin), or nuclear factor kappa B [toll-like receptor agonists such as imiquimod 
or CpG-ODNs; phosphoinositide 3-kinase (PI3Kγ) deletion]. The inhibition of placental growth factor (PlGF) (HRG) and C/EBPβ (PI3Kγ deletion) also leads to effective 
reprogramming of TAMs toward M1-like macrophages. Finally, by stimulating CD40, monoclonal antibodies (mAbs) against CD40 similarly reprogram TAMs from M2 
phenotype to M1 macrophages.
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The targeting of MMP-9 positive macrophages was also 
obtained with dasatinib, a tyrosine kinase inhibitor well 
tolerated by patients and approved by food and drug admin-
istration (FDA) for chronic myeloid leukemia (36). However, 
dasatinib has been reported to inhibit other immune cells 
as natural killer (NK) cells and T  cells, then aborting tumor 
immune response. Finally, trabectedin (ET-743), another drug 
approved by FDA, exhibited a cytotoxic effect against TAMs 
and showed antitumor activity. This drug was shown to not 
damage lymphocyte subgroups. This is due to the differential 
expression of TNFα-related apoptosis-inducing ligand receptor 
(TRAIL) (TNFα-related apoptosis-inducing ligand) receptor 
by the different types of leukocytes: trabectedin targets TAMs 
while human NK cells and CD8+ lymphocytes were resistant to 
TRAIL-mediated toxicity. In fact, blood monocytes and TAMs 
expressed higher level of TRAIL-R2 compared to NK cells and 
CD8+ lymphocytes (37, 38).
A second alternative is the use of toxin-conjugated 
monoclonal antibodies (mAbs) or attenuated bacteria that 
kill macrophages. An anti-scavenger receptor A (CD204) 
antibody conjugated to the saporin toxin reduced the number 
of vascular leukocytes and inhibited tumor progression in a 
murine ovarian cancer model (39). An immunotoxin composed 
of portions of anti-folate receptor beta antibody conjugated 
5Genard et al. Moderate X-ray Doses for TAM Reprogramming
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to Pseudomonas exotoxin A was also used to deplete TAMs: 
reduced tumor growth was observed in nude mice bearing C6 
glioma xenografts (40). In the same line, Shigella flexneri is a 
bacterial pathogen inducing the apoptosis of macrophages. 
Galmbacher and his colleagues developed an attenuated strain 
of S. flexneri to infect breast cancer-bearing mice. The treatment 
led to TAM depletion and to a complete tumor regression in 
tumor-bearing mice (41).
The last alternative is the activation of cytotoxic T lymphocytes 
against macrophages. Legumain is an asparaginyl endopeptidase 
that contributes to the degradation of the ECM and to angio-
genesis. TAMs have been found to express abundant amounts of 
legumain (42). This discovery led Smahel and his team to modify 
the gene sequence of legumain to enhance the efficacy of immu-
nization against legumain. These modifications induced reduced 
legumain maturation and impaired cellular localization, and 
resulted in T helper (CD4+) and cytotoxic (CD8+) lymphocyte-
dependent elimination of TAMs (43).
Depletion of macrophages has thus met successful results in 
the tumor regression in mouse models and patients. However, 
a systemic depletion of macrophages obviously renders the 
organism more sensitive to infections and other aggressions. 
Therefore, these types of treatments need to be localized to the 
tumor site.
inhibition of Circulating Monocyte 
Recruitment into Tumor
The inhibition of CCL2/C–C chemokine receptor type 2 or 
CSF1/CSF1-R pathways by several methods was shown to 
efficiently induce tumor regression (Figure  2B). CCL2 is a 
chemokine produced by cancer cells that is responsible for the 
recruitment of monocytes at the tumor site. CCL2 overexpres-
sion in tumor is correlated with macrophage infiltration and 
poor prognosis in human cancers (44–46). Furthermore, CCL2 
is a key actor of metastasis since it enhances the retention of 
metastasis-associated macrophages in breast cancer metastasis. 
CCL2 blockade was reported to block the mobilization of 
monocytes from the bone marrow to the blood in a murine 
breast cancer model (47). The inhibition of CCL2 by an anti-
CCL2 monoclonal antibody (e.g., carlumab) or through the 
inhibition of its synthesis (e.g., bindarit, trabectedin) prevented 
the recruitment of macrophages into the tumor site. Most of 
these treatments are now tested in clinical trials. Carlumab, a 
human monoclonal antibody against CCL2, was safely used 
in metastatic castration-resistant prostate cancer (48) and in a 
phase Ib study in association with other chemotherapy agents 
(docetaxel, gemcitabine, paclitaxel or carboplatin and pegylated 
liposomal doxorubicin) (49). This monoclonal antibody led 
to an efficient depletion of macrophages into the tumor and 
can significantly delay tumor regrowth following chemo-
therapy (49). Besides mAb targeting CCL2, other compounds 
(e.g., bindarit, trabectedin) were found to inhibit the synthesis 
of CCL2/MCP-1. Bindarit reduced TAM and myeloid-derived 
suppressor cell infiltration in a breast cancer model and resulted 
in impaired metastatic disease in a prostate cancer model (50). 
This treatment also targeted angiogenesis and tumor growth in 
human melanoma xenografts (51). In addition to deplete TAMs, 
trabectedin is used to inhibit monocyte recruitment. This drug 
targets CCL2 synthesis by interacting with the transcription 
machinery (52) but also modulates the DNA repair machinery 
(53). In clinic, it is used to treat ovarian and breast cancer as well 
as soft tissue sarcomas (53, 54).
Colony-stimulating factor 1/CSF1-R signaling drives the 
recruitment and the differentiation of TAMs toward a M2 phe-
notype in tumor. CSF1-deficient mice showed a 50% decrease 
in macrophage infiltration while neutrophil infiltration was 
increased during tumor progression in a mouse model of pan-
creatic islet cancer (55). mAbs and small molecules targeting 
CSF1 (mAb anti-CSF1) or CSF1-R (BLZ945, emactuzumab, 
PLX3397) were subjected to numerous studies and were shown 
to deplete macrophages in a tissue-specific manner (56, 57). 
Overall, CSF1-R inhibitors deplete TAMs and abolish tumor 
growth, angiogenesis, and metastasis. BLZ945, a highly selective 
small molecule inhibitor of CSF1-R tyrosine kinase, attenuated 
the turnover rate of TAMs while increasing the number of CD8+ 
T  cells in murine cervical and breast carcinoma models (56). 
In addition, blockade of CSF-1/CSF1-R by mAb anti-CSF1 or 
with PLX2297 (a small molecule targeting the tyrosine kinase 
domain of CSF1-R) was reported to reprogram remaining TAMs 
at the tumor site to support antitumor immunity in pancreatic 
cancer mouse models (58). PLX3397 also delayed the recurrence 
of glioblastoma after radiation by modifying the recruitment 
and polarization of myeloid cells in an intracranial xenograft 
model (59). However, orally administered PLX3397 showed no 
efficacy for human glioblastoma in a phase II study (60). Other 
chemoattractants for macrophages such as VEGF, C–X–C motif 
chemokine 12, CCL4 are also under investigation and may be 
considered as potential targets to inhibit macrophage recruitment 
and hence tumor progression.
Blockade of M2 Phenotype
Two main transcription factors have been largely reported to 
block M2 polarization: STAT 3 and STAT6 (Figure 2C). Tyrosine 
kinase inhibitors (sunitinib and sorafenib) inhibit STAT3 in 
macrophages. Sorafenib was shown to restore the secretion 
of IL-12 while suppressing IL-10 expression in prostaglandin 
E2-conditioned macrophages, indicating a reverse effect on the 
immunosuppressive cytokine profile in TAMs (61). Inhibition of 
STAT3 with WP1066 reversed immune tolerance in patients with 
glioblastoma multiforme. This treatment stimulated the secretion 
of pro-inflammatory cytokines and activated T cells (62). In the 
same line, resveratrol has also been used to suppress M2-like 
polarization of TAMs with parallel inhibition of tumor growth in 
a mouse lung cancer xenograft model. The blockade of M2-like 
polarization of TAMs by resveratrol was linked to the decreased 
activity of STAT3 (63).
Similarly, fenretinide (4-HPR) inhibited the phosphorylation 
of STAT6 and skew M2 polarization. In a colorectal mouse model, 
the effects were accompanied by a reduction in the number of 
M2-like macrophages in tumor and by an inhibition of angio-
genesis (64). Other inhibitors of STAT6 activation (TMC264, 
AS1517499) were developed but no one underwent clinical 
studies (65–67).
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enhanced Activation of M1 Phenotype or 
Reprogramming of TAMs toward M1-Like 
Macrophages
Several options are currently used to select M1 phenotype from 
TAMs or to reprogram TAMs from M2 to M1 phenotype: TLR 
agonists, mAb targeting inhibitory proteins of M1 phenotype as 
well as other compounds (Figure 2D). TLR agonists represent a 
promising antitumor therapy. However, different agonists have 
been shown to promote different immune responses. Imiquimod 
is a ligand of TLR7 and acts mainly by increasing the number of 
infiltrating CD43+ lymphocytes. This TLR agonist was found to 
induce the nuclear translocation of NFκB in J774A macrophages, 
leading to the production of pro-inflammatory proteins, such 
as TNFα, IL-6, IL-12, and CCL2 (68). The combination of 
topical imiquimod with low doses of cyclophosphamid and 
radiotherapy (RT) revealed a synergic antitumor effect and an 
increased survival response. This allowed the prevention of 
recurrence, with tumor rejection over 2  months after the end 
of treatment in a cutaneous breast cancer model (69). Multiple 
phase I and phase II clinical trials for imiquimod resulted in the 
use of topical application of imiquimod in clinic for skin metas-
tasis and carcinomas. Synthetic unmethylated cytosine-guanine 
(CpG) oligodeoxinucleotides (CpG-ODNs) also offered high 
immunostimulatory activity. These molecules act by enhancing 
the production of pro-inflammatory cytokines, such as TNFα, 
IL-6 and IL-12, in macrophages and by upregulating NFκB activ-
ity in these cells. Indeed, these nucleotides are frequently found 
in viral and bacterial genomes and are recognized as pathogen-
associated molecular patterns by TLR9 (70–72). Multiple studies 
aimed to improve the delivery of these CpG-ODNs by coupling 
them to gold nanoparticles for example (73). Combination of 
CpG-ODNs with other therapies, such as anti-CD40 exhibited 
promising results associated with the repolarization of TAMs 
(74, 75), even in poorly immunogenic cancer models such as a 
preclinical glioma model (76).
Another alternative to favor cytotoxic functions of TAMs is 
the stimulation of CD40 with mAbs. CD40 mAbs have demon-
strated antitumor T-cell responses in mouse models of cancer and 
in clinical trials (77). Macrophages also express CD40 in their 
plasma membrane. Anti-CD40 mAbs were shown to promote 
macrophage tumoricidal activity, especially through enhanced 
secretion of NO and TNFα. Hence, it could induce CD8+ T cell-
dependent inhibition of tumor growth and metastasis (78–80). 
Clinical studies revealed objective tumor response in solid 
tumors (81). Since anti-CD40 mAbs can induce programmed 
death ligand 1 (PD-L1) upregulation in TAM and tumor-
infiltrating monocyte plasma membrane, the blockade of PD-L1 
axis combined with anti-CD40 and anti-CTLA-4 (anti-cytotoxic 
T-Lymphocyte-associated protein 4) mAbs showed extensive 
survival in colon and breast cancer models (77). Finally, MARCO 
is a pattern recognition scavenger receptor and is expressed by 
immunosuppressive TAMs. The targeting of this receptor is a new 
promising way to treat mammary carcinoma, colon carcinoma, 
and melanoma through the reprogramming of immunosup-
pressive TAMs toward a pro-inflammatory phenotype and by 
increasing tumor immune response (82).
A third alternative to reprogram TAMs is the use of differ-
ent chemical compounds. The most famous one is IFNγ (83), 
approved by the FDA. In the same line, a small flavonoid-like 
compound, vadimezan (DMXAA), was found to repolarize 
macrophages in M1 phenotype. Reprogrammed macrophages 
then released cytokines and chemokines, including high local 
levels of TNFα, to induce a subsequent CD8+ T  cell activation 
(84). Vadimezan has been the subject of numerous preclinical 
studies and clinical trials. Alternatively, macrophage phospho-
inositide 3-kinase γ (PI3Kγ) was shown to control a critical switch 
between immune suppression and activation. Selective deletion 
of PI3Kγ simultaneously activates NFκB and inhibits C/EBPβ in 
macrophages. In combination with anti-PD-L1, PI3Kγ depletion 
promoted tumor regression and prolonged survival in head and 
neck, lung, and breast cancer murine models (85). The plasma 
protein histidine-rich glycoprotein (HRG) is also able to block 
TAMs into a M1 phenotype through the downregulation of the 
expression of the placental growth factor (PlGF), a member of 
the VEGF family. In mice, HRG promoted antitumor immune 
responses and normalization of the vessel network (86). Finally, 
metformin was shown to skew TAMs polarization into a pro-
inflammatory phenotype, partially through AMPKα1 activation. 
This effect was concomitant with a decrease in the number of 
metastases in Lewis lung cancer intravenous model (87).
While depletion of macrophages induced toxicities in mouse 
models and humans, the inhibition of macrophage/monocyte 
recruitment is one of the most used therapies in clinical stud-
ies. This type of therapy is usually combined to chemotherapy 
or RT and generated encouraging results in patients. On the 
other hand, the reprogramming of TAMs by chemotherapies or 
immunotherapies seems another very attractive way to target 
macrophages in tumors. However, there is a huge need for clinical 
studies to confirm these preclinical data in humans. Furthermore, 
it has to be noted that these treatments need to be localized to 
avoid an activation of M1 macrophages outside of the tumor and 
a systemic inflammatory response.
TARGeTiNG TAMs wiTH RT
In addition to target TAMs using chemo- and immunotherapies, 
it is also possible to influence the macrophage polarization with 
RT. Herein, we explore how low linear energy transfer (LET) 
radiotherapies (X-rays and γ-rays) can repolarize TAMs in vitro 
and in vivo. In a first part, the doses which have to be applied to the 
tumor in order to induce TAM reprogramming will be described 
and in a second part, the mechanisms involved in RT-induced 
reprogramming will be detailed.
Macrophage Radioresistance  
and Recruitment after RT
Macrophages are one of the most radioresistant cells in humans 
(7). This radioresistance is brought by a huge production 
of anti-oxidative molecules, such as manganese superoxide 
dismutase (MnSOD), a scavenger of superoxide (O2
−) ions. The 
high expression of MnSOD confers cellular resistance against 
damaging effects. These damaging effects are mainly produced 
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by radiation-induced radicals, such as ROS or reactive nitrogen 
species (RNS). Indeed, the expression of MnSOD was increased 
after irradiation in THP-1, HL60, and KG-1 myelocytic cell lines. 
The mechanism of radioresistance conferred to macrophages was 
shown to be dependent on TNFα signaling. Indeed, endogenous 
production of TNFα is required for MnSOD expression follow-
ing ionizing radiation (IR) (88–90). This TNFα-induced MnSOD 
expression is mediated by PKC-dependent activation of cAMP-
responsive element-binding protein-1/ATF-1-like factors and 
would be dependent on NFκB activation (90–92). Currently, the 
radioresistance provided by endogenous MnSOD to macrophages 
is mimicked in healthy cells using MnSOD plasmid/liposome 
gene therapy to confer radioresistance to healthy cells (93–95).
Radiotherapy is used for more than 50% of cancer patients and 
showed tumor regression in most of the cases (33, 96). However, 
in addition to the intrinsic radioresistance of macrophages, 
IR also elicits a high recruitment of myeloid cells at the tumor 
site, possibly leading to tumor recurrence and tumor regrowth 
(59). Depletion of macrophages by liposomal clodronate before 
IR promoted the antitumor effects of RT and highlighted the 
role of recruited TAMs in tumor regrowth (90). Macrophage 
recruitment after IR is mediated by CCL2 and CSF1. Indeed, RT 
stimulated CSF1 production in prostate cancer and was shown 
to be responsible for TAM accumulation (97). Similarly, the 
inhibition of CSF1 receptor with PLX3397 prevented the myeloid 
cells recruitment after IR, increased survival and postponed the 
recurrence of glioblastoma in intracranial xenograft models (59). 
RT also promotes macrophage infiltration, from the peritumoral 
environment to the tumor site, in a CCL2 dependent way (98, 99). 
However, to the best of our knowledge, there is no study combin-
ing RT to CCL2 inhibition described yet.
Dose-Dependent effects of irradiation  
on Macrophage Reprogramming
Although IR slightly affects the viability of macrophages, 
radiotherapy modifies the macrophage phenotype. To analyze 
the effects of radiotherapy on macrophage reprogramming, we 
classified these effects according to the dose. According to the 
UNSCEAR (United Nations Scientific Committee on the Effects 
of Atomic Radiation), low dose of X-ray radiation are doses 
under 0.1  Gy, but clinically applied low doses are doses under 
1 Gy (100). In this review, the irradiation doses were classified 
as followed: low doses as doses lower than 1 Gy, moderate doses 
(MDI) as doses ranging from 1 to 10 Gy, and high doses as doses 
higher than 10 Gy.
High Doses of Irradiation (HDI)
In vitro, M1 Raw264.7 macrophages were reprogrammed toward 
M2-like macrophages after HDI (20 Gy). Sustained M2 pheno-
type after irradiation resulted from NFκB p50 activation, leading 
to high IL-10 production and reduced TNFα secretion. These 
results were confirmed in  vivo since HDI (3  Gy ×  20  Gy over 
3 days) promoted M2-like macrophages at the tumor site, in mice 
with Panc02 cell xenografts (101). In another study, high doses 
of X-rays (25 Gy in one shot or 60 Gy fractioned over 3 weeks) 
increased the number of M2-like TAMs in a murine model of 
prostate cancer (TRAMP-C1 cell line). This was evidenced by a 
low inducible nitric oxide synthase (iNOS) level in macrophages 
and by an increase in Arg1 and COX-2 mRNA expression. Such 
high doses induced angiogenesis and tumor growth in this cancer 
model (7). An increased number of M2-like macrophages after 
high doses of radiation (12 Gy) was also observed in an oral can-
cer model. The recolonization of tumor by M2-like macrophages 
elicited the secretion of pro-angiogenic factors that contribute 
to neoangiogenesis, favoring tumor growth (102). In addition, 
Seifert et al. similarly described accelerated tumor growth after 
irradiation (12  Gy) of murine pancreatic tumor models. This 
was driven by an early infiltration of M2-polarized TAMs into 
the tumor after radiotherapy and resulted in a subsequent T-cell 
suppressive response. This T  cell response was linked to the 
upregulation of PD-L1 expression in tumor. The authors showed 
that RT accelerated the progression of pancreatic dysplasia to 
invasive carcinoma but also promoted tumor growth in invasive 
pancreatic ductal adenocarcinoma (PDA). Indeed, a decrease in 
iNOS, IRF5 and H2eb1 mRNA expression and a higher expres-
sion of Arg1, CD206, and PD-L1 were observed in TAMs from 
pancreatic dysplasia and PDA irradiated with hypofractionated 
(12 Gy) or fractionated (3 Gy × 6 Gy) doses (103). When TAMs 
were collected from tumor-bearing mice after RT and transferred 
to other tumor-bearing mice, tumor growth was accelerated to 
a higher extent than with unirradiated-macrophage transfer 
(7). Altogether, these results showed that HDI skew TAMs in a 
M2-like phenotype (Table 1). This is why the blockade of M-CSF, 
in order to prevent macrophage recruitment, in combination 
with HDI is attractive. Indeed, it revealed interesting results: 
M-CSF inhibition combined to RT promotes tumor regression. 
This reinforces the idea that HDI-irradiated TAMs take part to 
the tumor growth and tumor radioresistance. Furthermore, high 
levels of TAM-derived IL-10 elicited T cell anergy in irradiated 
tumor (103). This is why an adoptive CD4+ T cell transfer has 
not met any success, except with the use of anti-M-CSF therapy 
combined to RT. This observation highlights the necessity to 
reprogram macrophages toward a M1-like phenotype to over-
come the immunosuppression and the tumor regrowth after RT.
Moderate Doses of Irradiation (MDI)
In vitro, human unpolarized monocyte-derived macrophages 
shifted toward M1-like macrophages after MDI (2 Gy × 5). This 
is highlighted by the upregulation of pro-inflammatory markers 
(M1 phenotype) such as human leukocyte antigen-cell surface 
receptor (HLA-DR) and CD86, but also by the downregulation 
of anti-inflammatory markers (M2 phenotype) such as decreased 
mRNA expression of CD163, MRC1 (C-type mannose receptor 1, 
CD206) and versican (ECM proteoglycan) and reduced secretion 
of IL-10. In these macrophages, phagocytosis, associated with 
the M1-like phenotype, was increased after MDI while irradia-
tion did not influence the ability of cocultured macrophages to 
promote the invasion of cancer cells and angiogenesis, features of 
M2-like macrophages (104). In the same line, unpolarized Raw 
264.7 macrophages exhibited a higher expression of M1 markers 
(iNOS, TNFα, IL-12p70, IFNγ RANTES, and MCP-1) and a higher 
abundance of the phosphorylated p65 subunit from NFκB after 
γ-irradiation (2 Gy) (105). The γ-irradiation (2 Gy) of a human 
TABLe 1 | Macrophage reprogramming after HDI, MDI, and LDI.
Reference Dose Radiation 
type
effect on polarization Model
HDI (7) 4 Gy × 5 × 3 week = 60 Gy X-ray M2 polarization Mouse TRAMP-C1 (prostate)
(101) 20 Gy × 3/day X-ray M2 polarization Mouse Panc02 (pancreas)
(102) 12 Gy X-ray M2 polarization Human oral cancer (OSC-19 cells)—xenograft
(103) 12 Gy or 3 × 6 Gy X-ray M2 polarization Orthotopic pancreatic ductal adenocarcinoma model pancreas
MDI (108) 2 Gy × 5 (10 Gy) X-ray Mixed M1/M2 phenotype Human monocyte-derived macrophages (hMDM) with RKO or 
SW1463 cells
(105) 5–10 Gy X-ray Increased inducible nitric 
oxide synthase (iNOS)/nitric 
oxide (NO) production
Raw 264.7 stimulated with lipopolysaccharide (LPS)/interferon 
γ (IFNγ)
(104) 2 Gy × 5 X-ray Reduced M2 markers hMDMs
(107) 2–4 Gy γ-ray M1 polarization Raw 264.7, THP-1, hMDM
(33) 2 Gy γ-ray M1 polarization Raw 264.7 and peritoneal macrophages from RT5 mice
(96) 2 Gy γ-ray M1 polarization Tumor-associated macrophages from RT5 mice + CD8 T cell 
transfer (pancreas)
(118) 1–2 Gy X-ray M2 polarization Peritoneal macrophages from BALB/c mice + LPS/Raw 264.7
LDI (105) 0.3–0.6–1.25 Gy X-ray Decreased iNOS/NO 
production
Raw 264.7 stimulated with LPS/IFNγ
(109) 0.5–1 Gy X-ray M2 polarization Raw 264.7
(110) 0.5–0.7 Gy X-ray M2 polarization THP-1 monocytes + LPS and monosodium urate crystals
(111) 0.5–0.7 Gy X-ray Reduced M1 markers THP-1 monocytes + LPS and monosodium urate crystals
(112) 0.01–0.7 Gy X-ray M2 polarization Peritoneal macrophages/Raw 264.7
Red shading/font means M2 polarization, green shading/font means M1 polarization.  
HDI, high doses of irradiation; MDI, moderate doses of irradiation; LDI, low doses of irradiation.
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macrophage cell line (U937) also provoked a higher expression of 
TNFα and IFNγ compared to unirradiated macrophages (106). In 
another study, CD11b+/Gr-1 peritoneal macrophages from RT5 
mice were γ-irradiated (2 Gy) ex vivo and showed an increased 
iNOS expression, related to M1 phenotype (33). Finally, PMA-
differentiated macrophages (THP-1), murine macrophages (Raw 
264.7) and human monocyte-derived macrophages (hMDM) 
revealed a pro-inflammatory profile after moderate doses of 
γ-rays (2 and 4  Gy). This was evidenced by increased mRNA 
levels for TNFα, IFNγ, IL-6, and IL-23 and higher protein levels 
for IL-1β and IL-8. While most of the previous studies showed the 
activation of NFκB p65 for macrophage reprogramming, this last 
study revealed that IR-induced M1-like phenotype was promoted 
by the transcriptional expression of IRF5 and was ataxia telangi-
ectasia mutated (ATM)-dependent (107). Altogether, the results 
from in vitro experiment showed that unpolarized macrophages 
tend to acquire a M1 phenotype after MDI.
In addition to program unpolarized macrophages to M1 
phenotype, MDI also potentiated the already acquired M1 phe-
notype. Indeed, MDI (2 Gy × 5) promoted a pro-inflammatory 
profile in M1 macrophages stimulated with LPS/IFNγ, as indi-
cated by an increased expression of HLA-DR (104). Another 
in  vitro experiment revealed that doses under 1  Gy prevented 
the polarization of macrophages toward M1 phenotype whereas 
doses of 5 and 10  Gy promoted the M1 phenotype in murine 
Raw 264.7 macrophages when stimulated with LPS/IFNγ. This 
is emphasized by an increased expression of iNOS and a higher 
NO production in irradiated macrophages (105). In contrast, in 
hMDMs stimulated with M-CSF and IL-10 (M2 macrophages), 
MDI did not influence the expression of pro- and anti-inflam-
matory markers (104). In other words, the effect of MDI on 
polarized macrophages showed an enhanced M1 phenotype in M1 
macrophages but no change in M2 macrophages, meaning that 
MDI could not reprogram TAMs in vitro.
Cocultured experiments were performed between radiosen-
sitive (RKO cells) or radioresistant (SW1463 cells) colorectal 
cancer cell lines and human unpolarized monocyte-derived 
macrophages. After irradiation, the mRNA expression of some 
pro-inflammatory (CCR7, IL1β, CXCL8) markers was decreased 
whereas the mRNA expression of anti-inflammatory markers was 
unchanged when macrophages were cocultured with RKO cells. 
MDI also promoted cancer cell invasion and migration of cocul-
tured RKO cells. However, when macrophages were cocultured 
with SW1463 cells, there was an upregulation of the expression of 
pro-inflammatory (CCR7, CD80) and anti-inflammatory mark-
ers (IL-10 and CCL18) but no change of cancer cell migration and 
invasion. It means that following MDI, unpolarized macrophages 
adopt a different phenotype according to the type of cancer cells 
with which they interact (108).
Interestingly, in vivo experiments revealed promising results. 
A group of researchers suggested that moderated single dose 
(2  Gy) of γ-ray was able to completely reprogram TAMs in 
tumor. Klug and Prakash analyzed M1 (iNOS protein level, NO 
production) and M2 (Ym-1, Fizz-1 and Arg 1 protein level) 
markers in CD11b+ peritoneal macrophages from RT5 mice after 
whole-body irradiation (WBI). While untreated mice exhibited 
elevated expression of M2 markers in peritoneal macrophages, 
whole-body irradiated mice revealed increased M1 marker 
expression and decreased M2 marker expression. However, local 
irradiation was not able to modify the expression of M1 and M2 
markers when measured in tumor tissue lysate. As local MDI 
(1, 2, and 6 Gy) induced a decline of T cell infiltration, the authors 
used CD8+ T cell transfer in addition to local irradiation (2 Gy) to 
induce a shift in the polarization of TAMs toward a M1 phenotype 
TABLe 2 | Macrophage reprogramming after WBI.
Reference Dose Radiation type effect Model
(113) 0.2 and 2 Gy γ-ray M1 polarization WBI (without tumor)
(117) 0.075 and 2 Gy X-ray M1 polarization WBI (without tumor)
(114) 0.5–6 Gy X-ray M1 polarization WBI (without tumor)
(118) 0.01–0.02–0.1 Gy × 10/day × 2 weeks 
(LDI)
X-ray Increased cytotoxic activity and nitric oxide Macrophages from BALB (L1)/c and C57BL/6  
(Lewis lung cancer) mice (WBI)
(96) 0.5–2 Gy × 1 (MDI) X-ray M1 polarization Mouse RT5 insulinoma/Human MeWo melanoma 
xenograft/Human pancreas
(33) 2 Gy × 2 (MDI) γ-ray M1 polarization Rip1 Tag5 tumor-bearing mouse (WBI)
Green shading means M1 polarization.  
WBI, whole-body irradiation.
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and to promote T cell infiltration in tumor. Local irradiation in 
combination with CD8+ T  cell transfer induced an enhanced 
expression of IL-12p40 and IFNγ (M1 markers) and a reduced 
expression of IL-10 (M2 marker) in tumor tissue lysate. Indeed, 
the infiltration of tumor by T cells was exclusively dependent on 
the reprogrammed TAMs. When TAMs was depleted with CL 
treatment before local irradiation and CD8+ T cell transfer, there 
was an inhibition of T cell recruitment into irradiated tumors. 
The infiltration of CD8+ T cell into tumor is made feasible with 
the normalization of the vasculature. Indeed, pro-inflammatory 
macrophages elicited the normalization of the vasculature and 
allowed an efficient T  cell transfer, leading to the eradication 
of the tumor and an increased survival in irradiated RT5 mice. 
However, it remains elusive how CD8+ T  cell transfer impacts 
TAM reprogramming. Interestingly, local irradiation alone is not 
able to reprogram TAMs toward a M1-like phenotype. Then, it 
seems clear that CD8+ T cell transfer plays a role in macrophage 
reprogramming. The underlying mechanism needs to be further 
investigated (96) Table  1 summarized the effects of MDI on 
macrophage polarization described here above.
Low Doses of Irradiation (LDI)
Low doses of irradiation represents a good alternative in order 
to bypass the toxicities observed during intensive radiotherapy 
(HDI) (Table 1). However, LDI rather favor the M2 phenotype 
of TAMs. Indeed, LDI decreased the iNOS level and the NO pro-
duction in Raw 264.7 macrophages polarized in M1 phenotype, 
resulting in repolarization of M1 macrophages toward M2 phe-
notype (105). Other results in favor of a M2-like phenotype were 
described after low doses of γ-radiation in murine macrophages. 
Indeed, irradiation of murine macrophages (RAW 264.7) with a 
dose of 0.5 Gy inhibited MPK1 [mitogen-activated protein kinase 
(MAPK) phosphatase]. MPK1 dephosphorylates the MAPKs 
p38, c-Jun and ERK1/2 and the dephosphorylation of p38 was 
associated with a decrease in TNFα and IL1β levels. Irradiation 
(0.5  Gy) of RAW264.7 macrophages stimulated with LPS also 
led to a decrease in p38 phosphorylation and TNFα production 
(109). In addition, Frey and Lodermann showed that low doses 
of X-rays (0.5–0.7 Gy) induced an anti-inflammatory phenotype 
in LPS-activated human THP-1 cells as evidenced by reduced 
amounts of secreted IL-1β in the medium. This was linked to a 
lower p65 NFκB nuclear translocation and a weak p38 phospho-
rylation (110, 111). Closely related to these results, it was also 
demonstrated that doses under 2 Gy favored the repolarization 
of M1 macrophages into M2-like macrophages, as evidenced 
by an increased level of TGFβ in the culture medium. This was 
associated to a reduced nuclear translocation of p65 NFκB (112).
In conclusion, HDI and LDI show no effect on M2 to M1 
macrophage polarization while MDI clearly evoke TAM repro-
gramming. However, most of studies performed in this field are 
in  vitro experiments, i.e., macrophages alone with no contact 
with cancer cells. Further in vivo experiments should reinforce 
the results obtained by Klug et  al. with MDI. Furthermore, to 
our knowledge, no clinical study has been designed to analyze 
the effect of MDI on TAM reprogramming. It is thus difficult to 
transpose these data to the human tumors.
Whole-Body Irradiation
In vivo studies showed that exposure to low doses of WBI in 
healthy mice activated the innate immune cells including mac-
rophages (113–115) (Table 2). In healthy mice, a single dose of 
WBI resulted in a TH1 cytokine expression profile whereas frac-
tionated dose irradiation drove a TH2 shift in spleen and blood of 
mice (116). In the same line, single low doses (0.075 and 2 Gy) 
of total body radiation in healthy mice polarized peritoneal mac-
rophages toward M1 phenotype as indicated by increased IL-12 
and IL-18 secretion. This polarization is strongly linked to the 
activation of p65 NFκB and MyD88 a few hours after WBI (117). 
Only a few studies were published on WBI of tumor-bearing mice, 
as this treatment is irrelevant for human. However, as WBI would 
reprogram TAMs, studying the underlying mechanisms could be 
very helpful. A first study indicated that low doses (0.01–0.1 Gy) 
of WBI induced opposite effects on macrophages and NK cells 
in BALB/c radiosensitive mice and C57BL/6 radioresistant mice. 
Peritoneal macrophages exhibited a M1 phenotype in BALB/c 
mice, evidenced by an increased production of IL1β, IL-12 and 
TNFα. However, M2 macrophages were observed in tumor from 
C57BL/6 mice after WBI, partly elucidating the radioresistance 
of this mouse strain (118). Klug et al. also showed that peritoneal 
macrophages from RT5 mice, irradiated with a systemic dose of 
2 Gy, revealed a higher iNOS level and NO production whereas 
the expression of M2 markers was decreased in these mac-
rophages, indicating macrophage reprogramming. Furthermore, 
macrophages from total body irradiated mice, when transferred 
to tumor-bearing mice in parallel with CD8+ T  cell adoptive 
transfer, induced tumor regression, similar to local irradiation in 
combination with CD8+ T cell adoptive transfer (96). In parallel, 
Prakash et  al. described a switch of TAM polarization toward 
FiGURe 3 | Nuclear factor kappa B (NFκB) balance state after LDI, MDI, and 
HDI. Irradiation dose showed opposite effects on NFκB balance in 
macrophages: LDI or doses lower than 1 Gy did not modify the abundance 
of p50–p50 NFκB in macrophage nucleus after radiation. MDI or doses from 
1 to 10 Gy induced a switch of NFκB balance from the inactive homodimer 
(p50–p50) to the active heterodimer (p50–p65), correlated with a 
reprogramming of tumor-associated macrophages (TAMs). HDI or doses 
higher than 10 Gy were not able to change the NFκB balance, skewing TAMs 
in a M2 phenotype (HDI, high doses of irradiation; MDI, moderated doses of 
irradiation; LDI, low doses of irradiation).
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M1 phenotype when RT5 insulinoma bearing mice were treated 
by systemic irradiation (2 Gy/week on 2 weeks). Indeed, tumor 
lysates presented a higher expression of M1 markers [iNOS, 
pSTAT3, TNFα, IL-12 (p70)] and a lower expression of M2 mark-
ers (CD206, Fizz-1, Ym-1 and Arg1). Peritumoral macrophages 
showed an elevated iNOS expression and NO production after 
WBI, modifying the tumor microenvironment with the normali-
zation of the tumor vasculature.
To explain the discordance between local irradiation and WBI 
on the reprogramming of TAMs, the authors suggested that WBI 
allowed the mobilization of fresh reprogrammed macrophages 
from various lymphoid organs to infiltrate the tumor site and the 
surrounding microenvironment. Infiltration of tumor by repro-
grammed macrophages can result in the activation of antitumor 
T-cell responses and can thereby act as an “endogenous vaccine” 
(33) On the other hand, local irradiation is not able to invite 
macrophages from lymphoid organs to the tumor site. It could be 
hypothesized that the transfer of CD8+ T cells would induce mac-
rophage reprogramming in lymphoid organs. The combination of 
T cell transfer to irradiation would promote the normalization of 
the tumor vasculature, allowing tumor perfusion by CD8+ T cells 
and reprogrammed macrophages.
Molecular Pathways Responsible for the 
Repolarization of TAMs after RT
There are several mechanisms proposed to explain the influ-
ence of the irradiation dose on the polarization of TAMs. These 
mechanisms are partly different from those involved in the repro-
gramming mediated by chemotherapy and immunotherapy, and 
they include ROS, DNA damage, p50–p65 NFκB activation, and 
MAPK phosphorylation. The differences between the different 
doses could be due to the activation of different pathways accord-
ing to the dose, i.e., a switch in the NFκB subunit balance for 
moderate doses while high doses would induce apoptosis.
NFκB Balance
Nuclear factor kappa B plays an important role in the polarization 
of macrophages. It was shown that M2 macrophages acquired 
their phenotype under the effect of p50–p50 NFκB homodimer 
while M1 macrophages are answerable to p50–p65 NFκB heter-
odimer (24). Once p65–p50 NFκB is translocated into the nucleus, 
it allows the expression of pro-inflammatory mediators [TNFα, 
IL-1β, IL-6, IL-12(p40), IFNγ, CXCL10 and NOS2 (14)] whereas 
p50–p50 NFκB inhibits the expression of these genes. Indeed, 
several experiments revealed the need for p65 translocation to 
activate M1 polarization (24, 119). Crittenden and his colleagues 
evidenced that HDI (60  Gy) produced M2 phenotype through 
p50–p50 dimer activation, leading to a subsequent IL-10 produc-
tion (101). In the same line, low X-ray radiation dose (<1 Gy) 
reduced the translocation of p50–p65 NFκB in M1 activated mac-
rophages (112). LDI on human macrophages and LPS-activated 
THP-1 macrophages reduced the nuclear amount of p65 NFκB, 
a phenomenon also correlated to a decreased secretion of IL-1β 
(M1 cytokine) (110). Interestingly, Teresa Pinto et  al. revealed 
an enhanced phosphorylation of RelA (p65) in macrophages 
following MDI (2, 6, and 10 Gy), correlated to M1 repolarization 
(104). Hildebrandt et al. also evidenced the role of NFκB in TAM 
reprogramming in Raw264.7 macrophages after 2 Gy irradiation 
(105). In an in  vivo study, whole-body γ-irradiation (2  Gy)-
induced the phosphorylation of NFκB p65 in tumor lysate. The 
activation of NFκB p65 is closely related to a reprogramming of 
TAMs toward M1-like macrophages (33) (Figure 3).
In sepsis, a sustained activation of macrophages by LPS leads 
to a tolerance and a reprogramming of macrophages toward 
M2 phenotype. This reprogramming is driven by p21, involved 
in the shifting of the balance between p65–p50 and p50–p50 
NFκB dimers. Indeed, p21 deficiency is linked to a reduced 
DNA-binding affinity of the p50–p50 homodimer and a preva-
lence for the p65–p50 heterodimer in macrophages stimulated 
with LPS (120, 121). In some cases, ubiquitination is controlled 
by the phosphorylation of a protein substrate (122). Indeed, 
some effectors of the DNA repair machinery are described to be 
involved in the ubiquitin proteasome pathway and regulate p21 
protein level in ML-1 cells (myelocytic leukemia cell line) (123). 
Therefore, a high ubiquitination of p21 would lead to a lower 
level of p21 protein. This could be correlated with an increased 
p65–p50 DNA-binding affinity and could potentially favor a M1 
phenotype after IR. Further investigations are, however, required 
to understand the possible role of p21 in regulating the NFκB 
balance after IR.
ATM Kinase
Radiotherapy induces major effects on cells by creating DNA 
damage. DNA damage and ROS produced by γ-radiation 
(2–20 Gy) induced the phosphorylation of ATM in U937 human 
macrophage cell line (106). When DNA damage appeared, ATM 
plays a central role in the detection and the activation of the 
DNA repair machinery [for review see Ref. (124)]. The activation 
of ATM notably leads to the ubiquitination of NEMO (NFκB 
Essential Modulator), a subunit of the IKK complex, a few hours 
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after macrophage irradiation. The ubiquitination of NEMO is 
ATM-dependent as indicated by the reduced ubiquitination of 
NEMO when an ATM inhibitor (Ku5593) was used in combina-
tion with γ-rays (125). Ubiquitinylated NEMO then drives the 
activation of IKK complex in the cytoplasm. This activation goes 
through ubiquitination of IKβ and the subsequent degradation 
of this inhibitor by the proteasome. p65–p50 NFκB is, therefore, 
released in the cytoplasm and free to move into the nucleus where 
the heterodimer acts as a transcriptional factor [for review see 
Ref. (126)].
After γ-radiation (2 Gy), the phosphorylation of NEMO was 
followed by the activation of NFκB (p65). A subsequent upregula-
tion of M1 markers (CD86, CD40, HLA-DR, TNFα, IFNγ) and 
a reduced secretion of IL-4 (M2 marker) followed the activation 
of NFκB. These changes are partially generated by elevated 
ROS content in cells, as indicated by the increase or decrease 
in the phosphorylation of NEMO when U937 monocytic cells 
were irradiated and treated with l-buthionine sulphoximine 
or N-acetyl cysteine (NAC), respectively. Indeed, l-buthionine 
sulphoximine irreversibly inhibits γ-glutamylcysteine synthase, 
hence depleting GSH level and increasing ROS content. NAC is 
a potent antioxidant, known to decrease ROS level by increasing 
GSH levels (106). However, another team showed that γ-rays 
(0, 3, 6, and 10 Gy) induced NFκB activation in Raw 264.7 mac-
rophages, as highlighted by the degradation of the IKβ protein. 
The activation of NFκB was related to a higher NO production in 
macrophages. This phenomenon is dependent on DNA damage 
more than ROS level, since NAC did not affect NO production 
and IKβ degradation in irradiated cells (127).
Moreover, modulators of DNA repair, such as Olaparib 
(PARP inhibitor), increased ATM activation and upregulated 
IRF5 transcription, resulting in macrophage activation toward a 
pro-inflammatory phenotype (107). In conclusion, IR is able to 
induce DNA damage by direct or ROS-dependent interactions 
with DNA. DNA damage leads to the recruitment of the ATM 
kinase and DNA repair machinery. Consequently, ATM contrib-
utes to the reprogramming of macrophages after irradiation.
Reactive Oxygen Species
Radiation therapy promotes the formation of radicals, such as 
ROS or RNS in cells. ROS quantities depend on the dose applied 
to the cells. In macrophages, different ROS concentrations can 
differently influence the cellular responses and the polarization 
of macrophages. Indeed, the role of ROS in the polarization of 
macrophages is not so clear but the most accepted idea is that 
ROS play key roles in M1 responses (e.g., defense against invading 
microbes) (128) and regulates M2 polarization (129, 130).
M1 Polarization
The polarization of macrophages toward M1 or M2 phenotype 
goes through several pathways, including NFκB. There is a bal-
ance between the inhibitory heterodimer NFκB (p50–p50) and 
the active heterodimer NFκB (p50–p65) (24). When this balance 
leans on one side or the other, macrophages undergo M2 or M1 
polarization, respectively. It is also well known that ROS generation 
mediated the production of pro-inflammatory cytokines (131). 
Indeed, this ROS production activates MAPK and NFκB pathways 
(132). It was shown that H2O2 enhanced p65 NFκB DNA-binding 
and promoted p65 NFκB phosphorylation. This NFκB activation 
is followed by its translocation into the nucleus in macrophage 
and monocytic cell lines, and then induces M1 polarization 
(133). In parallel, it was shown that H2O2 altered protein–protein 
interaction of p50–p50 NFκB, therefore reducing p50–p50 NFκB 
activation, supporting M1 activation (134). As previously said, 
ROS production is observed after irradiation. This is due to the 
direct ionization of molecules by incident photons. Another 
way for γ-irradiation to induce ROS generation is the activation 
of NADPH oxidase (NOX). The NADPH oxidase (NOX 1 and 
NOX 2) catalyzes the oxidation of nicotinamide adenine dinucle-
otide in the NADP+ + H+ while reducing O2 in O2−, leading to the 
formation of H2O2. γ-irradiation (2 Gy) promoted ROS produc-
tion in Raw264.7. This ROS production was partly inhibited by 
the use of NAC and by diphenylene iodonium, a NOX inhibitor. 
In parallel, the protein expression of NOX2 was increased after 
γ-irradiation in PMA-differentiated THP-1 cell and in Raw264.7 
macrophages. Altogether, these results indicated that moderate 
doses of γ-irradiation generated NOX2-dependent ROS produc-
tion. Elevated ROS content yielded ATM activation, as suggested 
by the absence of ATM phosphorylation in presence of NAC 
or siNOX2 when Raw264.7 macrophages were irradiated. This 
NOX2-dependent ATM activation controlled the polarization of 
Raw 264.7, THP-1 and hMDM in M1-like macrophages, through 
the regulation of IRF5 transcription. Moreover, in patients, the 
perturbation of ATM-dependent NOX2 signaling pathway was 
associated with a decreased iNOS macrophage number and poor 
tumor responses to radiotherapy (107).
M2 Polarization
Not only, NAPDH oxidase activity drives M1 polarization, 
but its inhibition conversely triggers M2 polarization. A 
previous study showed that the inhibition of NOX promoted 
anti-inflammatory microglial activation (M2 phenotype) dur-
ing neuroinflammation (135). Furthermore, another group 
revealed that the deletion of NOX1/2 reduced ROS production 
during macrophage differentiation. This double knockout is not 
critical for M1-like polarization of mouse bone marrow-derived 
macrophages, but prevented M2 polarization, as evidenced by 
the reduced expression of mCCL17, mCCL24 and RELMα. 
Indeed, NOX1/2 is crucial for the activation of c-Jun N-terminal 
kinase (JNK) and extracellular signal-regulated kinase (ERK) 
MAPKs during monocyte to macrophage differentiation and 
then affects M2 polarization (136). High concentrations of ROS 
play a decisive role in the differentiation and the polarization 
of macrophages into M2 phenotype and antioxidants treatment 
affected M2 but not M1 macrophage polarization. The use of 
butylated hydroanysole and other ROS scavengers repressed 
tumorigenesis by blocking the occurrence of TAMs (129). H2O2 
stimulates the production of TNFα and activates the transcrip-
tion factor STAT6, responsible for the expression of M2 markers 
such as Fizz-1 in macrophages (137, 138).
All these data showed that high concentrations of ROS trigger 
M2 polarization while smaller concentrations are responsible for 
M1 polarization. On the one hand, the production of ROS driven 
by HDI prevents the reprogramming of TAMs toward M1-like 
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macrophages. On the other hand, LDI induce small ROS produc-
tion, probably not enough to reach the range of concentrations 
able to reprogram macrophages. However, MDI allows to reach 
the right range of ROS concentrations in macrophages to activate 
p65 NFκB, IRF5, and MAPK notably through ATM activation, 
hence favoring M1 phenotype.
Further investigations are needed to better understand the 
effect of IR on the ROS generation in TAMs and the molecular 
pathways involved in the polarization of macrophages via ROS 
production.
IRF5
Interferon-regulatory factor/signal transducer and activator 
of transcription (IRF/STAT) signaling is a central pathway in 
macrophage polarization. IRF can interact with two adaptors, 
MyD88 and TRIF, downstream of cytokine receptors or TLR. 
IRF5 and IRF4 are in competition to the binding of MyD88 and 
the subsequent activation of pro-inflammatory transcription 
factors, including NFκB. The activation of IRF5 through MyD88 
then promotes M1 phenotype in macrophages. As a competitor 
for MyD88, IRF4 acts as an antagonist and can suppress M1 
macrophage polarization. The balance between IFR4 and IRF5 in 
cells is critical for M2 and M1 polarization, respectively (24, 139).
Only one in  vitro study established the role of IRF5 in 
macrophage reprogramming after irradiation. In this study, the 
authors showed that macrophages acquired a M1-like phenotype 
after exposition to γ-irradiation (2 Gy). This polarization is made 
feasible by the activation of NOX2 and ATM, hence driving the 
transcription of IRF5 (107). While these results are very interest-
ing, the contribution of IRF/STAT pathway to macrophage polari-
zation mediated by irradiation needs to be further investigated 
in  vivo and in patients. Furthermore, IRF5 modulation is also 
known to drive M1 polarization through the activation of NFκB. 
The link between IRF and NFκB in macrophage reprogramming 
after radiotherapy should also be considered.
iNOS Level and NO Production
Nitric oxide mediator is a double-edge sword key regulator in 
tumor progression. On the one hand, NO has antitumoral effects 
as it promotes DNA damage, elicits cell death, and enhances 
anticancer therapeutic efficacy. Indeed, patients with lower iNOS 
expression levels, hence low NO production, showed recurrence 
of tumors and metastasis after RT. On the other hand, NO 
mediator is also known for its pro-tumoral effects since it induces 
antiapoptotic effects and promotes cell cycle, cancer progression, 
metastasis, angiogenesis, and chemoprotection. High level of 
iNOS is associated with poor prognosis and tumor-promoting 
effects (140). It thus seems that critical NO concentrations and 
iNOS levels finely modulate the fate of the tumor.
High doses of irradiation induced NO production and high 
iNOS expression level in macrophages. For instance, high doses of 
γ-irradiation (20 Gy) led to iNOS activation and NO production, 
favoring tumor growth and recurrence after RT (141). Another 
in  vivo study using high doses (25  Gy or 3  Gy ×  20  Gy) also 
generated high level of iNOS in murine macrophages after IR, 
contributing to the tumor growth (7). NO production contributes 
to DNA repair by inducing p53, poly(ADP ribose) polymerase 
and DNA-dependent protein kinase activation, leading to tissue 
regeneration and tumor regrowth. In addition, NO mediator 
is related to tumor angiogenesis and promotes reoxygenation. 
Therefore, targeting iNOS in murine macrophages enhanced 
postradiotherapeutic efficacy after HDI (141).
On the other hand, WBI (2 Gy × 2 Gy) on RT5 mice induced 
an increased NO production and iNOS level, enough to induce 
tumor regression. In addition, ex vivo radiation with similar doses 
on peritoneal macrophages from RT5 mice also stimulated an 
increased in iNOS level and NO production (33). Indeed, NO can 
be considered as a free radical and as a source of reactive oxygen 
and nitrogen species, inducing DNA damage (142). Another team 
hypothesized that iNOS and NO production induced by MDI 
(2  Gy) remodeled vasculature allowing cytotoxic lymphocyte 
recruitment, and subsequent tumor eradication (15). NO leads 
to higher tumor oxygenation by promoting vasodilatation and 
hence radiosensitization (142). It can diffuse toward bystander 
cancer cells leading to their radiosensitization (143).
High doses of irradiation would induce high level of NO in 
macrophages, leading to cancer progression. Contrarily, MDI 
drive a slight increase in NO production in macrophages, enough 
to participate to the reprogramming of TAMs and favoring tumor 
regression.
MAPK (p38–ERK–JNK)
Mitogen-activated protein kinases are serine threonine kinases 
activated by diverse stimuli including cytokines and ROS. MAPKs 
regulate diverse pathways such as cell proliferation, apoptosis, and 
differentiation. MAPKs include extracellular signal-regulated 
kinase 1 and 2 (ERK 1/2), JNK and p38. They mediate immune 
cell functional responses to diverse signals and play a role in 
macrophage polarization. MAPK kinases (MAPKKs) activate 
MAPKs through dual phosphorylation on tyrosine and threonine 
residues (Thr–X–Tyr motif) located in the activation loop of the 
kinase domain (144). The phosphorylation of MAPK activates 
pro-inflammatory gene transcription and is correlated with 
M1-like macrophages. At the opposite, MAPKs are inactivated 
through dephosphorylation of threonine and/or tyrosine residues 
within the activation loop by MAPK phosphatase (MKP-1) (145). 
MKP-1-deficient macrophages exhibit skewed activation profiles: 
macrophages showed an enhanced pro-inflammatory phenotype 
in response to IFNγ and TNFα while this deficiency severely 
suppressed “M2-like” phenotype after IL-4 stimulation (146). 
Compared to wild-type mice, MKP-1-deficient mice produced 
greater amounts of TNFα, IL-1β, CCL2, granulocyte/macrophage 
colony-stimulating factor (GM-CSF), IL-6, IL-10, and IL-12p70 
(147, 148).
Mitogen-activated protein kinases are also regulated by ROS 
and DNA damage (132). Within a few minutes, low doses (0.5 
and 1 Gy) of γ-radiation induced a dephosphorylation of both 
ERK 1/2 and p38 MAPKs. This dephosphorylation depended 
on MKP-1 and induced the suppression of TNFα production 
in Raw 264.7 cells. These results correlated with the inability 
of LDI to reprogram M2 macrophages (109). Another study 
showed enhanced phosphorylation of ERK 1/2 and p38 follow-
ing moderated doses (2  Gy) of γ-radiation in resident perito-
neal exudate cells. This activation was related to a decreased 
FiGURe 4 | Molecular mechanisms activated after moderated doses of irradiation in tumor-associated macrophages (TAMs). Ionizing radiation (X-rays or γ-rays) 
induces DNA damage and elevated reactive oxygen species (ROS) content in cells. DNA repair machinery [such as ataxia telangiectasia mutated (ATM)] is activated 
by DNA damage and initiates the ubiquitination of NFκB essential modulator (NEMO), a subunit of the IKK complex. Therefore, ubiquinated NEMO can drive the 
activation of IKK complex in the cytoplasm. The degradation of IκB protein by the proteasome allows the release of p50–p65 nuclear factor kappa B (NFκB) in the 
cytoplasm. p50–p65 NFκB is then translocated into the nucleus and induces the transcription of pro-inflammatory genes, leading to the reprogramming of TAMs. 
ROS are also able to stimulate mitogen-activated protein kinase (MAPKs). Once phosphorylated, MAPKs also participate to the activation of NFκB and hence, to the 
transcription of pro-inflammatory genes.
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dephosphorylation exerted by MKP-1 and was correlated with 
TNFα production. The explanation relies on the oxidation of the 
catalytic cysteine of MKP that inactivates the phosphatase, then 
triggering the activation of MAPK cascade including JNK and 
p38. These results correlated with the reprogramming of mac-
rophages induced by MDI (149). Conflicting results revealed the 
inhibition of p38 phosphorylation in macrophages after WBI of 
tumor-bearing mice. The inhibition of p38 phosphorylation 
in macrophages allowed the reprogramming of TAMs toward 
M1 phenotype in tumor. This inhibition could be linked to the 
upregulation of MKP-1 (33).
Nuclear Erythroid Derived 2-Related Factor (Nrf2)
The Nrf2 is involved in the management of intracellular oxidative 
stress. It is also known to repress inflammation by inhibiting pro-
inflammatory cytokine expression. Indeed Nrf2 is able to bind the 
close proximity of IL-6, IL-1β, and IL-1α genes in LPS-stimulated 
macrophages. This binding hence inhibits the recruitment of 
RNA polymerase II to the transcription start site without affect-
ing the p65 NFκB recruitment. The Nrf2 binding to these genes 
is independent on ROS level since the use of antioxidant (NAC) 
did not affect the inhibition of pro-inflammatory gene transcrip-
tion mediated by Nrf2 (150). The transcription factor Nrf2 was 
translocated into the nucleus even after 0.1  Gy γ-radiation, 
leading to the upregulation of antioxidant proteins such as heme 
oxygenase-1 in Raw 264.7. Nrf2 translocation increased with the 
dose (0.1–2.5  Gy). The regulation of Nrf2 is mediated by ERK 
1/2 pathway after the irradiation of macrophages (121). It is also 
known that in oxidative stress conditions, p21 interacts with 
Nrh2 domain of Nrf2, upregulating Nrf2-mediated antioxidant 
response (151). This could link the Nrf2 pathway to NFκB in the 
reprogramming of TAMs after IR: the absence of p21 prevents 
the anti-inflammatory response mediated by Nrf2 and favors the 
p50–p65 NFκB DNA-binding. The fate of irradiated macrophages 
would then depend on the connection between ROS level/DNA 
damage and the downstream-activated pathways.
Overall view Regarding TAM 
Reprogramming upon Radiotherapy
Local radiotherapy can finely tune the balance between immuno-
suppression and immune antitumor properties. The shift toward 
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one or the other immune state depends on the dose per fraction, 
the total dose and the cancer type. Whereas local IR finds dif-
ficulties to completely reprogram TAMs, WBI can be helpful in 
the understanding of TAMs reprogramming since it activates the 
immune system outside the tumor site, leading to the complete 
eradication of the tumor. It, thus, seems that local IR needs 
something more than its sole effects on macrophages to induce 
a total reprogramming of TAMs and to restore a full immune 
antitumor response.
The mechanisms underlying macrophage reprogramming 
after radiation therapy are summarized in Figure 4. This figure 
emphasizes the central role of NFκB in macrophage reprogram-
ming after MDI. Although most of these studies described in this 
review are promising, there is still a huge need for further investi-
gations and in vivo confirmations. Indeed, cancer cell irradiation 
generates damage-associated molecule patterns (DAMPs), such 
as high mobility group box 1 (HMGB1). DAMPs bind on their 
corresponding pattern-recognition receptor, such as TLR4 for 
HMGB1 in macrophages, triggering a pro-inflammatory pheno-
type (152). The irradiation then promotes antitumoral responses. 
However, it is possible that the contact between macrophages 
and cancer cells could offer the response of macrophages to 
radiotherapy. Indeed, cancer cells secrete different cytokines 
and chemokines that could influence the faith of macrophage 
polarization. More precisely, the type of cancer cells in the tumor 
can modulate macrophage reprogramming after irradiation, as 
evidenced by the opposite results acquired with different cancer 
cell lines in cocultured with macrophages (108).
In parallel, IR can also alter other types of cells in tumor, 
such as lymphocytes and dendritic cells, as well as the tumor 
vascularization (152). For example, ablative radiation therapy 
promotes CD8+ T cell accumulation into the tumor (153, 154). 
Indeed, single moderate doses (10 Gy) of irradiation mobilized 
CD8+ T cell through dendritic cells activation hence reducing 
or eradicating tumor. Therefore, MDI fulfills mobilization of 
effectors from the immune system and is able to reprogram 
TAMs in an antitumor phenotype. However, the issue about 
the fractionation should also be addressed, as in patients the 
treatments are usually given in several doses. It was shown that 
hyperfractionation (5  Gy ×  4  Gy) could completely abrogate 
the effect on CD8+ T  cell mobilization observed with single 
high dose (20 Gy) (154). The effects of fractionation on mac-
rophage reprogramming remain elusive and need to be further 
investigated.
CONCLUSiON AND FUTURe DiReCTiONS
Chemo- and immunotherapies, as well as moderate dose of irra-
diation are able to reprogram TAMs into M1-like macrophages. 
TAM reprogramming is induced through various mechanisms. 
These pathways mainly include NFκB, NO production, and 
STAT1 that can act together. MDI-induced reprogramming is 
made possible through DNA damage-dependent ATM activa-
tion, the production of a specific range of ROS and NO amounts, 
a shift of the NFκB balance to the active p50–p65 heterodimer, the 
transcription of IRF5 and the activation of the MAPK pathway. 
Amongst them, NFκB pathway seems to be a central target for 
macrophage reprogramming.
Local IR is able to kill cancer cells and to activate the immune 
system by the release of cancer cell antigens and of immune-
associated factors by stromal cells and vascular endothelial cells, 
but it also depletes T  cells and antigen-presenting cells (155). 
Combined radiotherapy and immunotherapy have shown prom-
ising results in reprogramming macrophages and may thus be 
useful for tumor elimination. However, the choice of T cell adop-
tive transfer can determine the fate of the tumor and macrophage 
reprogramming, as CD8+ T cell adoptive transfer is more effective 
than CD4+ T cell adoptive transfer (96, 103). Indeed, the use of 
a anti CD4+ T cell therapy combined to γ-irradiation (5 Gy) in 
a mammary mouse model improved the efficacy of radiotherapy 
(156). The use of MDI combined to adoptive CD8+ T cell trans-
fer or stimulating CD8+ T  cell therapy (such as anti PD-L1/
programmed cell death 1) may give promising results as effective 
anticancer therapies. The transfer of irradiated macrophages was 
also the subject of numerous studies in murine models. However, 
human clinical studies using transferred macrophages have also 
been performed but showed no or few improvements regarding 
cancer regression (157).
Another avenue to explore would be the effect of high LET 
particles, for example protons, since protontherapy is more and 
more developed in clinic. As the mechanism of action is differ-
ent from that of conventional radiotherapy (X-rays), the effects 
on macrophage reprogramming could be potentiated. Indeed, 
charged particles can drive huge NFκB activation compared to 
X-rays or γ-rays, as shown in HEK/293 cells (158).
Targeting the immune system in cancer diseases demonstrated 
successful improvement on cancer elimination and has become a 
highly promising therapy. Therefore, MDI combined to chemo- 
or immunotherapies targeting macrophage reprogramming 
could also synergize their effects on tumor regression.
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